# Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

> **NCT03307629** · PHASE1 · COMPLETED · sponsor: **Noxopharm Limited** · enrollment: 25 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** NOX66
- **RADIATION:** Irradiation Therapy

## Key facts

- **NCT ID:** NCT03307629
- **Lead sponsor:** Noxopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2020-09-15
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03307629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03307629, "Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03307629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*